Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

References

• NooneAM, HowladerN, KrapchoM, et al., eds. Cancer Statistics Review, 1975–2015 - SEER Statistics. SEER Cancer Statistics Review.
   Google Scholar
• HammondMEH, HayesDF, DowsettM, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–2795. doi:10.1200/JCO.2009.25.652920404251
   PubMed Web of Science ®Google Scholar
• HammondMEH. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol. 2011;19:499–500. doi:10.1097/PAI.0b013e31822a8eac22089488
   PubMedGoogle Scholar
• AllredDC, CarlsonRW, BerryDA, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Cancer Netw. 2009;7:S-1-S-21. doi:10.6004/jnccn.2009.0079
   Web of Science ®Google Scholar
• StoverDG, WinerEP. Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. Breast. 2015;24:S132–S135. doi:10.1016/j.breast.2015.07.03226255198
   PubMed Web of Science ®Google Scholar
• DentR, TrudeauM, PritchardKI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–4434. doi:10.1158/1078-0432.CCR-06-304517671126
   PubMed Web of Science ®Google Scholar
• SorlieT, PerouCM, TibshiraniR, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869–10874. doi:10.1073/pnas.19136709811553815
   PubMed Web of Science ®Google Scholar
• SorlieT, TibshiraniR, ParkerJ, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci. 2003;100:8418–8423. doi:10.1073/pnas.093269210012829800
   PubMed Web of Science ®Google Scholar
• LinNU, VanderplasA, HughesME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118:5463–5472. doi:10.1002/cncr.2758122544643
   PubMed Web of Science ®Google Scholar
• BauerKR, BrownM, CressRD, PariseCA, CaggianoV. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721–1728. doi:10.1002/cncr.2261817387718
   PubMed Web of Science ®Google Scholar
• PalSK, ChildsBH, PegramM. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627–636. doi:10.1007/s10549-010-1293-121161370
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. Natl Compr Cancer Netw. 2017. doi:10.1016/j.amepre.2011.02.015
   Web of Science ®Google Scholar
• LittonJK, RugoHS, EttlJ, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763. doi:10.1056/nejmoa180290530110579
   PubMed Web of Science ®Google Scholar
• RobsonM, ImS-A, SenkusE, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533. doi:10.1056/NEJMoa170645028578601
   PubMed Web of Science ®Google Scholar
• DominguesB, LopesJ, SoaresP, PopuloH. Melanoma treatment in review. ImmunoTargets Ther. 2018;7:35–49. doi:10.2147/itt.s13484229922629
   PubMed Web of Science ®Google Scholar
• BalkwillF, MantovaniA. Inflammation and cancer: back to Virchow?Lancet. 2001;357:539–545. doi:10.1016/S0140-6736(00)04046-011229684
   PubMed Web of Science ®Google Scholar
• HodiFS, O’DaySJ, McDermottDF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010. doi:10.1056/NEJMoa1003466
   Web of Science ®Google Scholar
• LarkinJ, Chiarion-SileniV, GonzalezR, et al. Combined nivolumab and ipilimumab or monotherapy in untreated Melanoma. N Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa150403026027431
   PubMed Web of Science ®Google Scholar
• PostowMA, ChesneyJ, PavlickAC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017. doi:10.1056/NEJMoa141442825891304
   PubMed Web of Science ®Google Scholar
• WeberJS, D’AngeloSP, MinorD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–384. doi:10.1016/S1470-2045(15)70076-825795410
   PubMed Web of Science ®Google Scholar
• RobertC, LongGV, BradyB, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330. doi:10.1056/NEJMoa141208225399552
   PubMed Web of Science ®Google Scholar
• RibasA, HamidO, DaudA, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600. doi:10.1001/jama.2016.405927092830
   PubMed Web of Science ®Google Scholar
• RibasA, PuzanovI, DummerR, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase 2 trial. Lancet Oncol. 2015;16:908–918. doi:10.1016/S1470-2045(15)00083-226115796
   PubMed Web of Science ®Google Scholar
• RobertC, SchachterJ, LongGV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. doi:10.1056/NEJMoa150309325891173
   PubMed Web of Science ®Google Scholar
• RobertC, RibasA, WolchokJD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117. doi:10.1016/S0140-6736(14)60958-225034862
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN Clinical Practice Guidelines in Oncology-Non-Small Cell Lung Cancer; 2016. doi:10.1016/0011-5029(88)90024-7
   Google Scholar
• BorghaeiH, Paz-AresL, HornL, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa150764326412456
   PubMed Web of Science ®Google Scholar
• BrahmerJR, HammersH, LipsonEJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Futur Oncol. 2015;11:1307–1326. doi:10.2217/fon.15.52
   PubMed Web of Science ®Google Scholar
• BrahmerJ, ReckampKL, BaasP, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoa150462726028407
   PubMed Web of Science ®Google Scholar
• AntoniaSJ, VillegasA, DanielD, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919–1929. doi:10.1056/NEJMoa170993728885881
   PubMed Web of Science ®Google Scholar
• FehrenbacherL, SpiraA, BallingerM, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846. doi:10.1016/S0140-6736(16)00587-026970723
   PubMed Web of Science ®Google Scholar
• GadgeelSM, StevensonJ, LangerCJ, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. J Clin Oncol. 2016;34:9016. doi:10.1200/JCO.2016.34.15_suppl.9016
   Web of Science ®Google Scholar
• MokTSK, WuYL, KudabaI, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830. doi:10.1016/S0140-6736(18)32409-730955977
   PubMed Web of Science ®Google Scholar
• GandhiL, Rodríguez-AbreuD, GadgeelS, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi:10.1056/NEJMoa180100529658856
   PubMed Web of Science ®Google Scholar
• SocinskiMA, JotteRM, CappuzzoF, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301. doi:10.1056/NEJMoa171694829863955
   PubMed Web of Science ®Google Scholar
• DirixLY, TakacsI, JerusalemG, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat. 2018;167:671–686. doi:10.1007/s10549-017-4537-529063313
   PubMed Web of Science ®Google Scholar
• DirixL, TakacsI, NikolinakosP, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. In: San Antonio Breast Cancer Symposium; 2014; San Antonio, TX, USA.
   Google Scholar
• AdamsS, LoiS, ToppmeyerD, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B. J Clin Oncol. 2017. doi:10.1200/jco.2017.35.15_suppl.1088
   Web of Science ®Google Scholar
• AdamsS, SchmidP, RugoHS, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017. doi:10.1200/jco.2017.35.15_suppl.1008
   Web of Science ®Google Scholar
• AdamsS, SchmidP, RugoHS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019. doi:10.1093/annonc/mdy517
   Web of Science ®Google Scholar
• EmensLA, CruzC, EderJP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a Phase 1 study. JAMA Oncol. 2019;5:74. doi:10.1001/jamaoncol.2018.422430242306
   PubMed Web of Science ®Google Scholar
• SchmidP, AdamsS, RugoHS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121. doi:10.1056/NEJMoa180961530345906
   PubMed Web of Science ®Google Scholar
• YamC, ManiSA, MoulderSL. Targeting the molecular subtypes of triple negative breast cancer: understanding the diversity to progress the field. Oncologist. 2017;22:1086–1093. doi:10.1634/theoncologist.2017-009528559413
   PubMed Web of Science ®Google Scholar
• GaraudS, BuisseretL, SolinasC, et al. Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 2019;13:5.
   Google Scholar
• HidaA, WatanabeT, SagaraY, et al. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer. Breast Cancer Res Treat. 2019;178:283–294. doi:10.1007/s10549-019-05390-x31402409
   PubMed Web of Science ®Google Scholar
• DenkertC, von MinckwitzG, Darb-EsfahaniS, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50. doi:10.1016/S1470-2045(17)30904-X29233559
   PubMed Web of Science ®Google Scholar
• WimberlyH, BrownJR, SchalperK, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res. 2015;3:326–332. doi:10.1158/2326-6066.CIR-14-013325527356
   PubMed Web of Science ®Google Scholar
• LipsonEJ, FordePM, HammersHJ, EmensLA, TaubeJM, TopalianSL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587–600. doi:10.1053/j.seminoncol.2015.05.01326320063
   PubMed Web of Science ®Google Scholar
• HavelJJ, ChowellD, ChanTA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–150. doi:10.1038/s41568-019-0116-x30755690
   PubMed Web of Science ®Google Scholar
• MahoneyKM, RennertPD, FreemanGJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561–584. doi:10.1038/nrd459126228759
   PubMed Web of Science ®Google Scholar
• NandaR, ChowLQM, DeesEC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib keynote-012 study. J Clin Oncol. 2016;34:2460–2467. doi:10.1200/JCO.2015.64.893127138582
   PubMed Web of Science ®Google Scholar
• RugoHS, DelordJP, ImSA, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer. Clin Cancer Res. 2018;24:2804–2811. doi:10.1158/1078-0432.CCR-17-345229559561
   PubMed Web of Science ®Google Scholar
• AdamsS, LoiS, ToppmeyerD, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019. doi:10.1093/annonc/mdy518
   Web of Science ®Google Scholar
• AdamsS, Gatti-MaysME, KalinskyK, et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 2019;5:1205. doi:10.1001/jamaoncol.2018.7147
   PubMed Web of Science ®Google Scholar
• Tecentriq [package insert]. 2018.
   Google Scholar
• SchmidP, ParkYH, Muñoz-CouseloE, et al. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173. J Clin Oncol. 2017;35:556. doi:10.1200/jco.2017.35.15_suppl.556
   Web of Science ®Google Scholar
• NandaR, LiuMC, YauC, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. J Clin Oncol. 2017;35:506. doi:10.1200/jco.2017.35.15_suppl.50628029304
   PubMed Web of Science ®Google Scholar
• BrahmerJR, LacchettiC, SchneiderBJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–1768. doi:10.1200/JCO.2017.77.638529442540
   PubMed Web of Science ®Google Scholar
• TawbiHA, ForsythPA, AlgaziA, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722–730. doi:10.1056/NEJMoa180545330134131
   PubMed Web of Science ®Google Scholar
• HarelM, OrtenbergR, VaranasiSK, et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. Cell. 2019;179:236–250.e18. doi:10.1016/j.cell.2019.08.01231495571
   PubMed Web of Science ®Google Scholar
• DuffyMJ, CrownJ. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019;65:1228–1238. doi:10.1373/clinchem.2019.30364431315901
   PubMed Web of Science ®Google Scholar
• SambiM, BagheriL, SzewczukMR. Current challenges in cancer immunotherapy: multimodal approaches to improve efficacy and patient response rates. J Oncol. 2019;2019:1–12. doi:10.1155/2019/4508794
   Web of Science ®Google Scholar
• Lee VentolaC. Cancer immunotherapy, part 3: challenges and future trends. Pharm Ther. 2017.
   Google Scholar
• KurraV, SullivanRJ, GainorJF, et al. Pseudoprogression in cancer immunotherapy: rates, time course and patient outcomes. J Clin Oncol. 2016;34:6580. doi:10.1200/jco.2016.34.15_suppl.6580
   Web of Science ®Google Scholar
• Stephen HodiF, BallingerM, LyonsB, et al. Immune-modified response evaluation criteria in solid tumors (imrecist): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018. doi:10.1200/JCO.2017.75.1644
   Web of Science ®Google Scholar
• FerraraR, MezquitaL, TexierM, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4:1543. doi:10.1001/jamaoncol.2018.367630193240
   PubMed Web of Science ®Google Scholar
• KwaMJ, AdamsS. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here. Cancer. 2018;124:2086–2103. doi:10.1002/cncr.3127229424936
   PubMed Web of Science ®Google Scholar